Navigation Links
K-V Pharmaceutical Secures Commitment for $85 Million Loan, Reaches Agreement with Senior Noteholders on Principal Terms of Plan of Reorganization
Date:12/12/2012

ST. LOUIS, Dec. 12, 2012 /PRNewswire/ -- K-V Pharmaceutical Company ("K-V" or "the Company") today announced that it has received a commitment from lenders led by an affiliate of Silver Point Finance LLC for $85 million in senior secured post-petition debtor-in-possession ("DIP") financing, which the Company intends to use to, among other things, satisfy the terms of its recently filed settlement agreement with Hologic, Inc. ("Hologic Settlement"), provide additional financial flexibility during the pendency of the Company's Chapter 11 proceeding and fund certain payments under a proposed reorganization plan.  The new DIP financing, the Hologic Settlement and the reorganization plan (and related disclosure statement)  are each subject to approval of the U. S. Bankruptcy Court for the Southern District of New York, the Honorable Judge Allan L. Gropper presiding.

The Hologic Settlement confirms K-V's continued ownership of Makena® and will resolve all bankruptcy related disputes between K-V and Hologic, and provides for mutual releases of all claims between the parties. 

Under the proposed reorganization plan, K-V expects to emerge from Chapter 11 with its entire product portfolio, including Makena®, Clindesse®, Gynazole-1® and Evamist®.  The Company has provided and is committed to continue to provide its women's health care products without interruption to meet the needs of the health care providers and patients it serves.

Prior to the funding of the DIP financing facility, K-V intends to file with the Bankruptcy Court a proposed reorganization plan, a related disclosure statement, and a plan support agreement (PSA) with an ad hoc group of senior secured noteholders.  The principal terms of the proposed reorganization plan are contained in a plan term sheet filed with the motion to approve the DIP financing filed with the Bankruptcy Court, which together with other documents from the Chapter
'/>"/>

SOURCE K-V Pharmaceutical Company
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. Internal and External Communications Excellence for the Pharmaceutical Industry: Increasing Organizational Effectiveness
3. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
4. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
5. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
6. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
7. The respective roles of the public and private sectors in pharmaceutical innovation
8. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
9. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
10. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
11. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... ... July 29, 2015 , ... G-CON Manufacturing, Inc., ... of their 2nd generation cell therapy POD® design. The 2nd generation portfolio not ... represents a new POD® design. , “G-CON first offered our miniPOD CT ...
(Date:7/29/2015)... CHICAGO , July 29, 2015  AmnioChor Inc., ... cell technology, is very pleased to announce that the ... has agreed to invest in their seed round ... OmniBank placental tissue storage capabilities. AmnioChor,s ... placenta, and the human stem cells living within those ...
(Date:7/29/2015)... , July 29, 2015  Indivior PLC (LON: ... for naloxone nasal spray was accepted and received Priority ... for the treatment of opioid overdose. This naloxone nasal ... specially formulated for optimal absorption into the nasal mucosa. ... minimal training so individuals may be better equipped to ...
(Date:7/29/2015)... /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS ) ... optimized Erk inhibitor molecule for development, thus achieving ... new class of potential cancer therapies. ... for therapeutic intervention in cancer. Recently approved compounds ... B-Raf and Mek inhibitors. Erk inhibitors may be ...
Breaking Biology Technology:G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 2G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 3The Musculoskeletal Transplant Foundation Agrees to Invest in AmnioChor 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 3Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 4Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 5Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3
... Mass.--Folding paper into shapes such as a crane or ... imagine trying to fold something that,s about a hundred ... it to use as an electronic device. , ... professor of mechanical engineering, is developing the basic principles ...
... Inc. (NASDAQ: VSGN ; TSX:VAS) today reported the results ... All dollar amounts referenced herein are in Canadian dollars unless ... cash equivalents totaled $8.6 million, compared with $23.5 million at ... As of January 31, 2009, our cash balance was $8.5 ...
... Feb. 27 Arkion(R) Life Sciences has received a ... Treatment in Louisiana effective March 1, 2009. The EPA ... protect field and sweet corn from marauding blackbirds and ... Avitec, Avipel(R) is applied to corn seed before planting ...
Cached Biology Technology:MIT uses nano-origami to build tiny electronic devices 2MIT uses nano-origami to build tiny electronic devices 3Vasogen Announces 2008 Year-End Results 2Vasogen Announces 2008 Year-End Results 3Vasogen Announces 2008 Year-End Results 4Vasogen Announces 2008 Year-End Results 5Vasogen Announces 2008 Year-End Results 6Vasogen Announces 2008 Year-End Results 7Vasogen Announces 2008 Year-End Results 8Vasogen Announces 2008 Year-End Results 9Vasogen Announces 2008 Year-End Results 10Vasogen Announces 2008 Year-End Results 11Crisis Exemption Granted to Market Avipel(R) Corn Seed Treatment in Louisiana 2
(Date:7/31/2015)... , Kina, 31. juli 2015 Den 10. ... afholdt af BGI fra den 22. - 25. oktober i ... Konferencen fejrer sin 10-års fødselsdag i år. Siden starten ... indflydelsesrige årlige møder på ,omik,-feltet, og er en af ... ICG-10 fokuserer på nylige gennembrud og fremskridt ...
(Date:7/31/2015)... , 31 de julio de 2015 ... (ICG-10,  www.icg-10.org ) del 22 al 25 de octubre ... La conferencia celebra su décimo aniversario este ... convertido en una de las reuniones anuales más influyentes ... es una de las conferencias científicas más dinámicas, entusiastas ...
(Date:7/31/2015)... China , 31 de julho de 2015 /PRNewswire/ ... (ICG-10, www.icg-10.org ) será realizada pela BGI de 22-25 ... . A conferência está celebrando seu ... em 2006, a ICG se tornou uma das reuniões ... um dos encontros científicos mais dinâmicos, entusiastas e prazerosos. ...
Breaking Biology News(10 mins):Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3
... Strasbourg 18/04/12 - Technology has transformed the way humans interact ... big ideas that will drive growth in marine and maritime ... and policy will gather at the 3rd Marine Board Forum ... Marine Board has convened this flagship event on the understanding ...
... April 2012 -- Several new studies that may help ... individual patients and of their tumors are being presented ... "A major goal of lung cancer treatment is ... Fiona Blackhall from The Christie NHS Foundation Trust in ...
... can be used to boost an enzyme,s function by as much ... detergents and a host of other products. In a paper ... team led by Pratul Agarwal of the Department of Energy,s Oak ... nature and it happens in the blink of an eye. ...
Cached Biology News:New technologies for a blue future 2Advances in personalized medicine for lung cancer 2Advances in personalized medicine for lung cancer 3Advances in personalized medicine for lung cancer 4Advances in personalized medicine for lung cancer 5ORNL process improves catalytic rate of enzymes by 3,000 percent 2